Az emlődaganatok primer szisztémás kemoterápiára adott válasza az immunhisztokémiai fenotípus tükrében
Authors:
- Janina KulkaJKJanina Kulka
- Anna-Mária TőkésATAnna-Mária Tőkés
- Adrienn Ildikó TóthATAdrienn Ildikó Tóth
- Attila Marcell SzászASAttila Marcell Szász
- Andrea FarkasAFAndrea Farkas
- Katalin BorkaKBKatalin Borka
- Balázs JárayBJBalázs Járay
- Eszter SzékelyESEszter Székely
- Roland IstókRIRoland Istók
- Gábor LotzGLGábor Lotz
- Lilla MadarasLMLilla Madaras
- Anna KorompayAKAnna Korompay
- 1 December 2009
- journal article
- abstracts
- Published by Akademiai Kiado Zrt. in Magyar Onkologia
- Vol. 53 (4) , 335-343
Abstract
The purpose of the study was to identify breast cancer subtypes by immunohistochemistry likely to respond to neoadjuvant chemotherapy and to analyze the used chemotherapy regimen and the range of response rates. Analysis of a collected database was performed. Ninety-two patients were identified in our files who received neoadjuvant chemotherapy between 1998 and 2009. We used immunohistochemical profiles (ER, PgR, HER2, Ki-67 and p53) of NCB, FNAB and surgical breast specimens to subclassify the tumors. Pathological response rates were assessed following surgical removal of tumors by using the Chevallier classification. DFS and OS was measured in 88 cases from the date of definitive surgery to the date of last follow-up or death. Pathological complete or near-complete remission (pCR = Chevallier I and II) was observed in 13 of 92 cases (14.1%). According to the preoperative characteristics of the 13 tumors achieving pCR, 9 of the cases were triple negative, one of 13 was ER-/HER2+ and three of 13 ER+/HER2+. Twenty-four of 92 patients received taxane based neoadjuvant chemotherapy, 30 of 92 anthracycline based neoadjuvant chemotherapy, 33 of 92 taxane + anthracycline regimen and 2 of 92 CMF regimen. In the taxane treated group of patients the pCR rate was 29.1%, in the anthracycline group 6.6% and in the taxane + anthracycline treated group 12.1%. Concerning DFS, significant difference was observed between the Chevallier III and IV groups (p=0.006), and less events were observed in the pCR group (not significant). pCR was associated with significantly better OS (p=0.050). It seems that even limited, routinely used immunohistochemical profiling of tumors is able to predict the likelihood of pCR to neoadjuvant chemotherapy. Patients with triple negative and HER2-positive cancers are likely to achieve pCR after neoadjuvant chemotherapy.Keywords
This publication has 32 references indexed in Scilit:
- The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancerBreast Cancer Research and Treatment, 2009
- Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumabAnnals of Oncology, 2008
- Triple negative tumours: a critical reviewHistopathology, 2007
- The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer SubtypesClinical Cancer Research, 2007
- Neoadjuvant Therapy with Paclitaxel followed by 5-Fluorouracil, Epirubicin, and Cyclophosphamide Chemotherapy and Concurrent Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: An Update of the Initial Randomized Study Population and Data of Additional Patients Treated with the Same RegimenClinical Cancer Research, 2007
- Prognostic Value of Pathologic Complete Response After Primary Chemotherapy in Relation to Hormone Receptor Status and Other FactorsJournal of Clinical Oncology, 2006
- Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancerBritish Journal of Cancer, 2004
- The Effect on Tumor Response of Adding Sequential Preoperative Docetaxel to Preoperative Doxorubicin and Cyclophosphamide: Preliminary Results From National Surgical Adjuvant Breast and Bowel Project Protocol B-27Journal of Clinical Oncology, 2003
- Inflammatory Breast CancerAmerican Journal of Clinical Oncology, 1993
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958